Plain-English translation of NCT07191730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a new computer-based tool designed to predict which patients receiving anthracycline chemotherapy or HER2-targeted therapies for cancer are at highest risk of developing heart problems. Researchers will follow 600 cancer patients over one year to gather information about their heart health and identify early warning signs. The goal is to create a better prediction score that helps doctors catch heart damage earlier and manage it more effectively.
Some of the most effective cancer treatments can damage the heart over time, but doctors currently lack reliable tools to predict which patients will have this problem. This study aims to fill that gap by using artificial intelligence to analyze patient data and create a better early warning system.
You likely qualify if…
You likely don't qualify if…
You will visit a heart-cancer specialist clinic before your cancer treatment begins for a baseline evaluation. Then, over the next 12 months, you'll have regular heart monitoring appointments—including heart imaging tests, blood tests to check for heart damage markers, and routine clinical care. All of this happens as part of your normal cancer treatment plan; researchers will simply collect and analyze the data to develop and test their new prediction tool.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France